Visitors must have compliant masks

August 14, 2020 Providence News Team

Share this Article
Facebook
Twitter
Email
LinkedIn

Some visitors are using masks from home that have been found ineffective, including masks with exhalation valves. They allow unfiltered air to escape and post a potential health risk to others.

These masks will be viewed as non-compliant; users will be asked to change to a mask provided by Providence. Visitors will also be given the option of adding an additional mask over the top; this can be added into practice, now.

See the flyer for more details

About the Author

The Providence News Team brings you the updates to keep you informed about what's happening across the organizational ecosystem. From partnerships to new doctor announcements, we are committed to keeping you informed.
More Content by Providence News Team

Grateful patients thank providers, care teams - Aug. 2020

Being a provider or other member of the care team requires years of training, sometimes long hours, and emo...

Providence Head and Neck Cancer Surgeons Use New Transoral Robotic Technology to Improve Surgical Outcomes

Providence Cancer Institute head and neck surgeons are some of a few nationwide, that are using a new trans...

Other content in this Stream

Can photo-immunotherapy improve outcomes in advanced solid tumors?

Visitors must have compliant masks

About the Author

Previous Article

Next Article

Other content in this Stream

Providence Cancer Institute to offer a new phase I/II study of a first-in-class photoimmunotherapy for solid tumors that overexpress the epidermal growth factor receptor protein.

Researchers at the Earle A. Chiles Research Institute, a division of Providence Cancer Institute, will join oncology professionals around the world for the 2021 ASCO Annual Virtual Conference.

Researchers at Providence’s Center for Outcomes Research and Education (CORE) have received a $430,000 Kuni Foundation grant to study disparities in cancer screenings.

Immunology leader Dr. Walter Urba talks about his healthcare journey and how Providence is defining the future of personalized care.

Providence Cancer Institute to offer phase II clinical trial of neoadjuvant chemotherapy plus immunotherapy for patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Portland’s first African American Baptist church, Mt. Olivet, has opened a temporary vaccination clinic, funded by Providence Health & Services and Kaiser Permanente.

Learn about important news from Providence Heart and Cancer institutes, CME opportunities, the new “Doc Talks” series and more.

“Get out and exercise in the fresh air, drink plenty of (clean) water, and eat healthy, fresh foods.” This is common advice we give our patients, families and ourselves to maintain and improve health.

Newly published data show a significant increase in the incidence of colorectal cancer among younger populations.

Two important things for you to know: 1. Vaccinations are free and appointments are encouraged. 2. You do not need health insurance or identification.

Providence's Glenda Fossum-Smith shares how one experience changed her view of the homelessness pandemic.

Being a provider or other member of the care team requires years of training, sometimes long hours, and emotional conversations with patients and their families.

Read about new leadership changes at Providence that affect providers and care teams.

Providence Cancer Institute’s Marka Crittenden, M.D., Ph.D., has been named the recipient of the new Michael Kelley Endowed Chair for Cancer Research.

“Get out and exercise in the fresh air, drink plenty of (clean) water, and eat healthy, fresh foods.” This is common advice we give our patients, families and ourselves to maintain and improve health.

This year, the annual Doctors’ Day takes on additional meaning. The past year of COVID-19 has brought challenges no one could have anticipated or prepared for.

Learn about a potential immune benefit for infants from lactating mothers who have received a COVID-19 vaccine.

New clinical trial at Providence Cancer Institute combining targeted therapy with checkpoint immunotherapy for patients with metastatic thyroid cancer.